Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Effect on Midazolam PK in Advanced Solid Tumors
NCT02686164Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2016
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lenvatinib in solid tumor and Differentiated Thyroid Cancer (DTC), sponsored by Eisai Co., Ltd. Primary endpoints: Area Under the Concentration-time Curve (AUC0-24) for Midazolam and 1'-Hydroxymidazolam and Maximum Observed Plasma Concentration for Midazolam and 1'-Hydroxymidazolam. Started Apr 2016; status: completed.
02
Drugs
lenvatinib
03
Conditions
solid tumorDifferentiated Thyroid Cancer (DTC)
Beyond the preview
Go deeper on NCT02686164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686164.